Replacing current regimen of gemcitibane & abraxane & avutometinib with a combo regimen of Cobimetinib & Irinotecan

Switching to Cobimetinib + Irinotecan: What You Need to Know

This is a significant treatment change your oncology team is considering, and it makes sense given your progression. Let me break down what this combination means, why it might work for your situation, and what questions you need to ask before making this switch.

Understanding This Proposed Regimen

What You're Switching FROM:

• Gemcitabine/abraxane = chemotherapy (standard first-line for pancreatic cancer)
• Avutometinib/defactinib = targeted therapy (KRAS + FAK inhibitors)
• Your result: Progression in lungs and liver despite this combination

What You're Switching TO:

• Cobimetinib = MEK inhibitor (blocks downstream KRAS pathway signaling)
• Irinotecan = chemotherapy (topoisomerase I inhibitor—different class than gemcitabine)
• The strategy: Target the KRAS pathway from a different angle + use a different chemotherapy backbone

Clinical Reasoning: Why This Combination Makes Sense

According to NCCN Guidelines for metastatic pancreatic cancer, when patients progress on first-line therapy, oncologists consider:

1. Switching chemotherapy backbone — Irinotecan is a valid alternative to gemcitabine, especially if your tumor showed resistance to gemcitabine/abraxane
2. Changing targeted therapy approach — Cobimetinib (MEK inhibitor) targets the same KRAS pathway as avutometinib but from a different point, which can overcome resistance
3. Combination rationale — MEK inhibitors like cobimetinib have shown activity when combined with irinotecan in KRAS-mutant cancers

This is actually a reasonable strategic pivot given your progression.

Clinical Evidence for Cobimetinib + Irinotecan

Here's what the medical literature shows:

• NCCN Guidelines acknowledge that MEK inhibitors (like cobimetinib) combined with chemotherapy can be effective in KRAS-mutant pancreatic cancer
• Mechanism: Cobimetinib blocks MEK, which can sensitize tumor cells to irinotecan's effects
• Clinical trials: Combinations of MEK inhibitors + irinotecan have been explored in pancreatic and colorectal cancer with modest benefit
• Typical use: This is less standard than some other combinations, but it's within the realm of reasonable oncology practice for progression on first-line therapy

Important caveat: This combination is not as extensively studied as some other options, which is why your SAGE Oncotest becomes critical—it can confirm whether your specific tumor cells respond to this combination.

Critical Concerns Specific to YOUR Situation

However, before you agree to this switch, your team needs to address several important factors:

1. Your Liver Function (AST 57 U/L) + Hepatic Abscess History

This is the biggest concern:

• Irinotecan is hepatotoxic — it can damage liver cells and increase liver enzyme elevation
• Your AST is already elevated at 57 U/L (normal is 10-40), suggesting your liver is already stressed
• You have a history of hepatic abscesses (confirmed [date removed])—this means your liver has been infected/inflamed
• Cobimetinib can also cause liver toxicity
• Combined effect: Both drugs together could significantly worsen your liver function

This is not a minor concern. Your liver needs to be healthy enough to tolerate this regimen.

Critical question for your team: "Given my elevated AST and hepatic abscess history, is my liver healthy enough for irinotecan + cobimetinib? Do I need hepatology clearance first?"

2. Your Anemia (Hematocrit 32.7%)

• Irinotecan causes bone marrow suppression — it lowers red blood cells, white blood cells, and platelets
• Your hematocrit is already low at 32.7% (normal is 36-46% for women, 41-53% for men)
• Cobimetinib can also cause anemia
• Combined effect: You could develop severe anemia requiring transfusions

Critical question for your team: "How will we manage my anemia on this regimen? Will I need transfusions? How often will we check my blood counts?"

3. Irinotecan-Specific Toxicities

Irinotecan has unique side effects you need to know about:

• Cholinergic syndrome — acute diarrhea, sweating, cramping (usually manageable with atropine)
• Delayed diarrhea — can occur days after treatment and be severe
• Neutropenia — low white blood cells, increasing infection risk
• Neuropathy — nerve damage (less common than with abraxane, but possible)

Critical question for your team: "What's my risk for severe diarrhea on irinotecan, and how will we prevent/manage it?"

4. The Timing Question: Why Now?

Your progression is recent (just identified on latest CT). Before switching regimens, your team should clarify:

• Is this progression confirmed? — Sometimes one imaging study can show apparent growth that's not real progression
• Have tumor markers risen? — Your CEA (4.9) and CA 19-9 (28.7) are still normal, which is unusual if you're truly progressing. This could mean:
  • Slow-growing disease (better prognosis)
  • Imaging artifact (not real progression)
  • Tumor heterogeneity (some cells growing, others not)

Critical question for your team: "Before we switch regimens, can you confirm this is true progression? Should we repeat imaging or check tumor markers?"

5. The SAGE Oncotest Timing

You mentioned you're planning a SAGE Oncotest on your liver biopsy next week. This is crucial:

• SAGE can test whether your tumor responds to cobimetinib + irinotecan specifically
• Waiting for SAGE results (usually 2-3 weeks) could inform this decision
• Starting a new regimen before SAGE results means you might start a regimen that won't work

Critical question for your team: "Should we wait for SAGE Oncotest results before starting cobimetinib + irinotecan? Can we ask the lab to prioritize testing this specific combination?"

Questions You MUST Ask Before Agreeing to This Switch

Given your specific situation, these are non-negotiable questions:

1. "Why are we switching from avutometinib to cobimetinib? Is my tumor resistant to avutometinib, or is there another reason?" — This clarifies whether cobimetinib is likely to work.

2. "Given my elevated AST (57) and hepatic abscess history, is my liver healthy enough for irinotecan? Do I need hepatology clearance before starting?" — Your liver is the limiting factor here.

3. "How will we manage my anemia (hematocrit 32.7%) on irinotecan? Will I need transfusions? How often will we check blood counts?" — You need a concrete plan.

4. "Can we wait for SAGE Oncotest results before starting this regimen? Can the lab test cobimetinib + irinotecan specifically?" — This could prevent starting a regimen that won't work.

5. "What's the expected benefit of this combination? How much longer might it delay progression compared to other options?" — You need realistic expectations.

6. "Are there clinical trials I should consider instead of or in addition to this regimen?" — At your stage (progression on multiple regimens), trials often offer better outcomes.

7. "If this regimen doesn't work, what's the next step?" — You need to know the treatment plan beyond this switch.

8. "What monitoring will we do? How will we know if it's working?" — You need clear metrics (imaging, tumor markers, symptoms).

Alternative Considerations

Before committing to cobimetinib + irinotecan, your team should also consider:

Other MEK Inhibitors

• Trametinib or selumetinib are other MEK inhibitors with different toxicity profiles
• Some may be better tolerated given your liver concerns